No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014. uri icon

Overview

publication date

  • June 27, 2014

Research

keywords

  • Acute Coronary Syndrome
  • Adenosine
  • Advisory Committees
  • Clinical Trials as Topic
  • Clinical Trials, Phase III as Topic
  • Drug Approval
  • Information Dissemination
  • Purinergic P2Y Receptor Antagonists
  • Randomized Controlled Trials as Topic
  • Ticlopidine
  • United States Food and Drug Administration

Identity

Scopus Document Identifier

  • 84925485534

Digital Object Identifier (DOI)

  • 10.1016/j.ijcard.2014.06.029

PubMed ID

  • 25005338

Additional Document Info

volume

  • 176

issue

  • 1